Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDER's 2017 New Drug Class Maintains Steady Innovative Composition With Recent Years

Executive Summary

New drugs approved in 2017 were not significantly different than those from years past in terms of innovative characteristics, but accelerated approval percentage took a sharp drop.

You may also be interested in...



Orphan Drugs Compose Majority Of Novel US Approvals For First Time Ever In 2018

Orphan drugs and priority reviews achieved historic highs in CDER's 2018 novel approval class, but share of products with breakthrough therapies took a slide. 

US FDA Likely To Shatter Novel Approval Record In 2018

With at least 40 pending novel products, FDA seems poised to break its 2017 approval record of 46, and could even reach 60.

US FDA Approval Climate: What Do The Oral Testosterone Reviews Tell Us?

Second go-round for oral testosterone could have marked new boundary on how far FDA is willing to go in approving new entrants to a market with widespread historic off-label use and CV risks.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel